Autolus Therapeutics plc
NASDAQ: AUTL0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Christian Martin Itin
- Employees
- 647
- Headquarters
- London, United Kingdom
- IPO year
- 2018
- Market cap
- $423.2M
- Website
- https://www.autolus.com
Loading AUTL…
Loading profile data…Frequently asked questions about AUTL
What does Autolus Therapeutics plc (AUTL) do?
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 tr...
Where does AUTL trade?
Autolus Therapeutics plc (AUTL) trades on the NASDAQ Global Select.
What sector is AUTL in?
Autolus Therapeutics plc (AUTL) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Autolus Therapeutics plc?
Christian Martin Itin is the chief executive officer of Autolus Therapeutics plc (AUTL).
Where is Autolus Therapeutics plc headquartered?
Autolus Therapeutics plc is headquartered in United Kingdom.
Does AUTL pay a dividend?
Autolus Therapeutics plc (AUTL) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did AUTL go public?
Autolus Therapeutics plc (AUTL) completed its initial public offering in 2018.
Is AUTL an ADR?
Yes — AUTL is an American Depositary Receipt; its underlying shares trade on a non-US exchange. Autolus Therapeutics plc reporting and dividends follow the underlying issuer.